肺癌管理中的生物标志物:改变胸部肿瘤学实践
本文综述了靶向治疗和免疫治疗时代肺癌生物标志物检测的挑战与进展,强调肿瘤分子特征检测是靶向治疗的必要组成部分。由于肺癌肿瘤样本常有限,液体活检在管理中尤为重要。检验医学是多学科肺癌管理不可或缺的部分。
要点
- 靶向治疗转向针对特定肿瘤驱动突变的药物,分子特征检测成为必要环节。
- 肺癌生物标志物检测面临肿瘤样本量常有限的特定挑战。
- 液体活检在肺癌管理中具有特别重要的意义。
核心结论
- 肺癌靶向治疗的发展使肿瘤分子特征检测成为靶向治疗的必要组成部分。
- 液体活检因肺癌肿瘤样本常有限而在管理中尤为重要。
- 检验医学是肺癌多学科管理不可或缺的部分。
主要发现
- 过去十年肺癌药物治疗的实质性进展与靶向治疗(包括免疫治疗)的出现相关。
- 靶向治疗已从抑制肿瘤生长和进展的一般机制逐渐转向针对特定肿瘤驱动突变等转化机制。
临床怎么用
- 肺癌管理需将分子特征检测纳入靶向治疗决策。
- 在肿瘤样本有限时,应考虑液体活检用于生物标志物检测。
- 检验医学应参与肺癌多学科管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer currently represents a leading cause of cancer death. Substantial progress achieved in the medical therapy of lung cancer during the last decade has been associated with the advent of targeted therapy, including immunotherapy. The targeted therapy has gradually shifted from drugs suppressing general mechanisms of tumor growth and progression to agents aiming at transforming mechanisms like driver mutations in a particular tumor. Knowledge of the molecular characteristics of a tumor has become an essential component of the more targeted therapeutic approach. There are specific challenges for biomarker determination in lung cancer, in particular a commonly limited size of tumor sample. Liquid biopsy is therefore of particular importance in the management of lung cancer. Laboratory medicine is an indispensable part of multidisciplinary management of lung cancer. Clinical Chemistry and Laboratory Medicine (CCLM) has played and will continue playing a major role in updating and spreading the knowledge in the field.
引用
- Melichar B. Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. Clin Chem Lab Med. 2022. PMID: 36384005. doi:10.1515/cclm-2022-1108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。